Cingulate Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
1901 W. 47TH PLACE, KANSAS CITY, KS, 66205
Mailing Address
1901 W. 47TH PLACE, KANSAS CITY, KS, 66205
Phone
(913) 942-2300
Fiscal Year End
1231
EIN
863825535
Financial Overview
FY2025
$15.07M
Total Assets
$7.46M
Stockholders' Equity
$12.21M
Cash & Equivalents
$-4.44
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13D/A Beneficial ownership amendment | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 24, 2026 | View on SEC |
| S-3/A Shelf registration amendment | March 23, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | March 20, 2026 | View on SEC |
| 8-K Current report of material events | March 18, 2026 | View on SEC |
| 10-K Annual financial report | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
Annual Reports
10-K
March 18, 2026
- CTxOneThreeZeroOne NDA submitted to FDA in Q4 2025, a critical step towards potential market approval.
- CTxOneThreeZeroTwo Phase 3 clinical trial started in Q3 2025, actively enrolling patients and advancing the pipeline.
Material Events
8-K
Leadership Change
December 15, 2025
High Impact
- Cingulate Inc. CEO Dr. Shane Schaffer has returned to his role after being on administrative leave since August.
- Dr. Schaffer's leave was due to a personal legal matter, which is now resolved; he pleaded 'no contest' to a misdemeanor and received 12 months probation.
Insider Trading
BUY
4 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.